The day at a glance · 6 sections · 4 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
Market Context
Democratic Sweep
Healthcare Market Overview
Regeneron Liver Fat Reduction
80%
Big Pharma & Biotech Pipeline
J&J PSA Response Rate
73%
Big Pharma & Biotech Pipeline
Key driverClinical trial readouts from Regeneron and Johnson & Johnson, combined with political tailwinds from Democratic midterm victories, boosted healthcare investor confidence
Daily briefHealthcare· Money365.Market AI ·
Healthcare Stocks Rally on Regulatory, Clinical Momentum
Regeneron liver fat data, J&J prostate cancer results, and GLP-1 treatment combinations drive sector optimism amid Democratic midterm sweep
Healthcare Market Overview
BullishMRNAXERSVIR
01
Healthcare stocks emerged as clear beneficiaries of the Democrats' sweeping victory in the November 3 midterm elections, as investors reassessed the outlook for federal healthcare spending. With Democrats gaining control of both the House and Senate, expectations of potential changes to Medicaid funding and Affordable Care Act subsidies helped fuel a rally across the sector.
02MRNA▲ +5.27%
Moderna ($MRNA), Xeris Biopharma ($XERS), and Vir Biotechnology ($VIR) shares surged to annual highs on Friday as Wall Street optimism grew and markets awaited trial data.
03MRNA▲ +5.27%
Moderna ($MRNA) continues to build its proprietary software into cancer drugs, creating a front-end design moat that rivals may struggle to replicate.
Big Pharma & Biotech Pipeline
Bullish01REGN
Regeneron Pharmaceuticals ($REGN) announced that single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks in MASLD patients. Data from the first-in-human trial were shared in an oral presentation at AASLD The Liver Meeting and simultaneously published in The New England Journal of Medicine. Regeneron will host a virtual investor event to discuss its MASH pipeline programs on Tuesday, November 10 at 8:30 a.m. ET.
02JNJ
Johnson & Johnson ($JNJ) announced promising first-in-human Phase 1 results for the investigational combination of pasritamig and JNJ-9401, two bispecific antibodies designed to work together to drive the body's immune response against advanced prostate cancer. At the recommended regimen, 73 percent of patients achieved reductions of at least 50 percent in prostate-specific antigen, a marker used to monitor prostate cancer activity.
03REGN
Regeneron Pharmaceuticals ($REGN) reported new long-term Phase 3 data for Libtayo in high-risk cutaneous squamous cell carcinoma, highlighting sustained disease-free and overall survival outcomes in patients treated with Libtayo adjuvant therapy despite high crossover rates. The company also expanded its U.S. government agreement with BARDA for additional Inmazeb supply to support infectious disease preparedness efforts.
04ABBV
AbbVie ($ABBV) announced results from HARMONY IN DIVERSITY and HALO, two Phase 4 studies of aesthetic treatment in adults on glucagon-like peptide-1 medications. HARMONY IN DIVERSITY is the first study to evaluate a neurotoxin combined with hyaluronic acid injectables in this population, with participants reporting statistically significant improvements in satisfaction with facial appearance and skin quality.
MedTech & Devices
NeutralSmith & Nephew Q3 Revenue
$1.55B+3.4%
01ISRG▼ -3.36%
Intuitive Surgical ($ISRG) placed 546 da Vinci Systems last quarter, though a Wall Street sell-off followed as the company's revenue model relies primarily on recurring usage rather than system sales. A fund with $4.5 billion in U.S. equities, Alphinity Investment Management, sold all of its Intuitive Surgical ($ISRG) shares in the third quarter according to its latest 13F filing.
02SNN
Smith & Nephew ($SNN) lowered its full-year revenue and trading profit outlook after continued weakness in its U.S. knee and hip businesses tempered otherwise stronger third-quarter growth. The medical technology company reported third-quarter revenue of $1.55 billion, up 3.4% on both reported and organic bases.
GLP-1 & Obesity Market
BullishNovo Analyst Upside
34%
01AMGN
Amgen ($AMGN) announced that an experimental drug could reduce 52 injections to just four a year for obesity patients, potentially offering a significant convenience advantage in the crowded GLP-1 market. The development comes as competitors continue to advance their own dosing regimens.
02NVO
Novo Nordisk ($NVO) Q3 results eased oral cannibalization fears, with analysts suggesting 34% upside potential as the company's quarterly performance demonstrated that oral formulations have not significantly impacted injectable demand as some had feared.
International Developments
BullishAlmirall Net Sales
€889.2M+8.3%
Almirall EBITDA
€221.7M+22.7%
Almirall EBITDA Margin
24.9%
01ALM
Almirall ($ALM), a global pharmaceutical company dedicated to medical dermatology, announced its results for the first nine months of 2026. Net Sales rose 8.3% year-over-year to €889.2 million and EBITDA grew 22.7% to €221.7 million, representing a margin of 24.9%. With steady performance in line with its long-term growth trajectory, Almirall reiterated its full-year 2026 guidance.
Looking Ahead
Neutral01REGN
Regeneron Pharmaceuticals ($REGN) will host a virtual Regeneron Roundtable investor event to discuss its MASH pipeline programs on Tuesday, November 10 at 8:30 a.m. ET, providing additional details on its metabolic disease strategy following the CIDEB siRNA data release.
Important Disclaimer — Not Investment Advice
Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.
Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest
Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.
- You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
- Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
- Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
- Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
- We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
- Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
- Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.
Full terms: Disclaimer · Terms of Service · Privacy Policy